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Despite extensive research, influenza A virus (IAV) remains a major cause of morbidity,
mortality, and healthcare expenditure. Emerging pandemics from highly pathogenic IAV
strains, such as H5N1 and pandemic H1N1, highlight the need for universal, cross-
protective vaccines. Current vaccine formulations generate strain-specific neutralizing
antibodies primarily against the outer coat proteins, hemagglutinin and neuraminidase.
In contrast to these highly mutable proteins, internal proteins of IAV are more conserved
and are a favorable target for developing vaccines that induce strong T cell responses
in addition to humoral immunity. Here, we found that intranasal administration with a
single dose of CpG and inactivated x31 (H3N2) reduced viral titers and partially protected
mice from a heterosubtypic challenge with a lethal dose of PR8 (H1N1). Early after
immunization, vaccinated mice showed increased innate immune activation with high
levels of MHCII and CD86 expression on dendritic cells in both draining lymph nodes and
lungs. Three days after immunization, CD4 and CD8 cells in the lung upregulated CD69,
suggesting that activated lymphocytes are present at the site of vaccine administration.
The ensuing effector Th1 responses were capable of producing multiple cytokines
and were present at least 30 days after immunization. Furthermore, functional memory
responses were observed, as antigen-specific IFN-γ+ and GrB+ cells were detected early
after lethal infection. Together, this work provides evidence for using pattern recognition
receptor agonists as a mucosal vaccine platform for inducing robust T cell responses
capable of protecting against heterologous IAV challenges.
Keywords: immunization, CpG, influenza A virus, nasal mucosa, vaccines, cytotoxic T lymphocytes, CD4 T
lymphocytes, CD8 T lymphocytes
Introduction
Influenza A viruses (IAV) cause annual outbreaks of upper respiratory tract infection and
induce severe infections in nearly three to five million people per year (1). In addition,
IAV induces occasional pandemics, making it a prominent pathogen today. Influenza A virus
outbreaks occur due to high rates of viral mutations in the outer coat proteins and reas-
sortment of viral RNA segments stemming from antigenic drift (2) and antigenic shift (3),
Abbreviations: CTL, cytotoxic T lymphocyte; GrB, granzyme B; IAV, influenza A virus; IFN-γ, interferon gamma; PR8,
influenza A/Puerto Rico/8/34; TNF-α, tumor necrosis factor alpha; x31, influenza A/Hong Kong/1/1968-X31.
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respectively. Due to these unpredictable events and poor pre-
dictive modeling, protection by current vaccines can be greatly
reduced in some influenza seasons (4). For example, vaccine effec-
tiveness has been shown to be 70–90% when circulating strains
are well matched, but <50% if antigenic mutations occur (5).
Influenza has increased deleterious effects on people at both ends
of the age spectrum, with increased morbidity in the elderly and
health complications in young children. Thus, the ability of the
influenza virus to mutate and evade host immunity coupled with
inadequate vaccines for at-risk populations highlights the need to
develop a more universal influenza vaccine.
Current influenza vaccines are designed to generate humoral
immunity against hemagglutinin (H) and neuraminidase (N) pro-
teins in the vaccine strain. Master seed stalks are developed from
either cold-adapted live virus or inactivated virus consisting of
prevalent H1N1, H3N2, and one or two influenza B strains. Thus,
the generation of high antibody titers and seroconversion to outer
coat proteins in the vaccine strains are the main mechanisms of
protection. However, antibodies induced by these vaccines have
significant limitations if antigenic variation occurs. Therefore,
universal vaccine approaches are currently being explored based
on the fact that immunization with conserved influenza pro-
teins elicits protection in many animal models following a lethal
heterosubtypic challenge (6–8).
One approach to universal influenza vaccines is based on
broadly neutralizing antibodies (9, 10). The majority of these
studies focus on generating antibody responses to the stalk region
of the HA protein that interfere with the ability of receptor-
binding motifs to bind to sialic acid or inhibit fusion with the
endosomal membrane, thus preventing infection. While broadly
neutralizing antibodies can mediate sterilizing immunity, prob-
lems still persist with these approaches including low titers of
stalk neutralizing antibodies after infection and/or overcoming
the immune response to the immunodominant globular head of
HA (11).
A second approach is to target T cells by vaccination. Suc-
cessful universal IAV vaccines not only induce T cell responses
with cytokine-producing and cytotoxic capabilities but also
induce helper T cells responsible for generating optimal antibody
responses (12) and maintaining CD8 memory (1). Furthermore,
influenza-specific T cells not only respond to surface antigens
but are also capable of mounting strong protective responses to
much less variable regions of the influenza proteome including
the nucleoprotein (NP),matrix (M), and polymerase proteins (13–
15). Thus, T cell-based vaccines can be directed toward internal
antigens that are well conserved between IAV subtypes and can
circumvent outer coat mutations and viral escape variants to
initiate protective immune responses.
As natural infection generates high levels of antigen-specific
cells (16), CD8 cytotoxic T lymphocytes (CTL) responses have
been established as a key cell type important for heterosubtypic
infection. However, CD8 CTL is not the only cell type implicated
in heterosubtypic protection.A role forCD4 cells is nowbecoming
increasingly appreciated in establishing protection against het-
erologous IAV infections. Supporting observations for the impor-
tance of CD4 T cells include a role for cytolytic CD4 cells (17).
These cells, via perforin dependent cytotoxicity in the absence
of antibodies, have been shown to be important for protection
against a lethal viral challenge (12, 18). Furthermore, vaccine
platforms that induce T cell responses have translational applica-
tions as pre-existing memory T cells specific to internal influenza
proteins have been associated with less virus shedding and lower
symptom scores in humans (13, 19). Therefore, cell-mediated
immunity should be able to provide a broad range of protection
against serologically distinct viruses.
Consistently boosting and maintaining high levels of antigen-
specific memory T cells still have not been achieved in humans
as current influenza vaccines do not universally boost T cell
responses across vaccinated individuals. One way to enhance vac-
cine efficacy and boost cellular responses is through the addition
of adjuvants (20, 21). Unmethylated CpG, a TLR9 agonist, is
currently being examined as an adjuvant in a number of clin-
ical applications ranging from vaccine development to cancer
immunotherapy (22). CpG is an attractive vaccine adjuvant not
only for its potent immunostimulatory properties but also for its
excellent stability, tolerability, and metabolism within a host.
Like IAV infection, CpG administration induces a Th1-biased
response. Many of the immunological reactions that CpG induces
result in adaptive responses that share a common mechanism
with IAV infection. Indeed, both human and mouse studies have
demonstrated that administration of CpG allows for enhanced
T cell interferon-gamma (IFN-γ) production and CTL responses
with antiviral capabilities in vitro and in vivo. (23–25). Because
of the adjuvanticity in inducing robust T cell responses, CpG
combined with inactivated influenza makes for a promising vac-
cine candidate. Here, we show that a single dose of CpG and
inactivated influenza via the mucosal route promotes the devel-
opment and differentiation of effector T cells that persist into
memory and confer partial protection against a heterosubtypic
influenza challenge. The current study highlights the evidence for
the generation of a universal influenza vaccine that could not only
provide protection against seasonal IAV variants but also highly
virulent, potentially pandemic infections.
Materials and Methods
Mice
Male BALB/cByJ mice were purchased from Jackson Laboratories
(RRID:IMSR_JAX:001026). Mice 6–8weeks old were used in all
experiments. Experimental animal procedures using mice were
approved by and conducted in accordance with the Institutional
Animal Care and Use Committee (IACUC) at the University of
Nebraska-Lincoln.
Mouse Immunizations
For all immunizations, mice were under anesthesia using an
isoflurane vaporizer. Mock immunized animals received 30µl of
PBS intranasally. For some groups, IAV was heat inactivated at
70°C for 1 h. One cohort of mice received 10µl of inactivated
virus containing 107 EID50 A/HKx31-OvaII (x31/Ova), diluted
in PBS for a total volume of 30µl. A separate cohort of mice
received 50µg of CpG (ODN1826; Invivogen San Diego, CA,
USA) combined with 107 EID50 inactivated x31/Ova diluted in
PBS. For x31/Ova priming,micewere anesthetizedwith isoflurane
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and infected with 950 EID50 x31/Ova virus also administered
intranasally.
Influenza Virus Challenge
For challenge experiments, mice were anesthetized with isoflu-
rane, and A/Puerto Rico/8/1934 (PR8) was diluted in PBS and
administered intranasally in a total volume of 30µl. PR8 viruses
were used at a sublethal dose of 0.1 LD50 or at a challenge dose of
either 1 LD50 or 10 LD50. For challenge experiments, mice were
infected with a lethal dose of PR8 4–6weeks post immunization.
Influenza viruses were generously provided by Dr. Paul Thomas,
St. Jude Children’s Research Hospital (x31/Ova) or the Trudeau
Institute (PR8).
Extraction of RNA and Real-Time qRT-PCR
Mice were euthanized at various times following intranasal
inoculation, lungs placed immediately in RNAlater (Ambion,
Austin, TX, USA) and frozen at  20°C. The samples were
weighed and homogenized in TRIzol (Ambion) at 1ml/100mg
of lung tissue using a Tissue Tearor homogenizer (Biospec
Products Inc., Bartlesville, OK, USA). RNA was isolated from
lung homogenates, reverse-transcribed into cDNA, and ampli-
fied by quantitative real-time PCR (Step One Plus, Applied
Biosystems) as previously described (26). Specific primers
for murine TLR9 (Mm00446193_m1), IL-6 (Mm0044619_m1),
TNF-α (Mm00443258_m1), MIP-1β (Mm00443111_m1) were
purchased from Applied Biosystems. The following murine
primer/probe sets were purchased from Integrated DNA Tech-
nologies (Coralville, IA, USA):
IFN-α4
50-/56-FAM/TTTGGATTC/ZEN/CCCTTGGAGAAGGTGG/
3IABKFQ/-30 (probe),
50-GCCTTCTGGATCTGTTGGTTA-30 (forward)
50-GCCTCACACTTATAACCTCGG-30 (reverse)
CXCL10
50-/56-FAM/ATCCCTCTC/ZEN/GCAAGGACGGTC/
3IABKFQ/-30 (probe),
50-TGATTTCAAGCTTCCCTATGGC-30 (forward),
50-ATTTTCTGCCTCATCCTGCT-30 (reverse)
To determine the viral titer, the following acid polymerase (PA)
probe and primers were used:
50-/56-FAM/CCAAGTCAT/ZEN/GAAGGAGAGGGAATACC
GCT/3IABkFQ/-30 (probe)
50-CGGTCCAAATTCCTGCTGAT-30 (forward),
50-CATTGGGTTCCTTCCATCCA-30 (reverse)
A known concentration of PA-containing plasmid was used to
generate a standard curve in all reactions. PA copies per lung were
then calculated based an initial concentration of 100 ng of cDNA
as described (12, 26).
Isolation of Lung and Lymph Node Cells for Flow
Cytometry
Mice were euthanized at various times post infection, and
lungs, draining lymph node (DLN) cells (a pool of mediastinal
and cervical lymph nodes), or spleens were processed as
described for flow cytometry analysis (26). Briefly, lungs were
perfused with PBS, treated with collagenase D, and filtered
through a 70-µm filter. DLN and spleens were dissociated
into single cell suspensions and stained with fluorochrome-
conjugated antibodies to CD4 (eBioscience Cat# 45-0042-
80, RRID:AB_906231), CD8 (eBioscience Cat# 11-0081-82
RRID:AB_464915), CD49b (eBioscience Cat# 14-5971-85,
RRID:AB_467767), TLR9 (eBioscience Cat# 11-9093-80
RRID:AB_465443), F4/80 (eBioscience Cat# 45-4801-
80, RRID:AB_914344), CD103 (BioLegend Cat# 121405
RRID:AB_535948), CD69 (eBioscience Cat# 12-0691-82
RRID:AB_465732), CD11c (eBioscience Cat# 45-0114-82
RRID:AB_925727), CD11b (eBioscience Cat# 17-0112-
81 RRID:AB_469342), I-Ad (BD Biosciences Cat# 553548
RRID:AB_394915), and CD86 (BD Biosciences Cat# 553692
RRID:AB_394994) for 30min at 4°C. In some experiments,
isolated lymphocytes were surface stained, fixed in 4%
paraformaldehyde, and stained with anti-human GrB (Invitrogen
Cat# MHGB05 RRID:AB_1500190) antibody to measure
intracellular levels of GrB protein in effector T cells. Cells were
acquired using a FACS Calibur (BD Biosciences) or Cytek DxP10
(Cytek Development, Fremont, CA, USA) flow cytometer and
analyzed using FlowJo software (FlowJo, RRID:nif-0000-30575).
Restimulation with Peptides for Cytokine
Analysis
For intracellular cytokine assays, cells were isolated from the
lungs as described above and restimulated with IAV peptide
pulsed A20s (ATCC, Manassas, VA, USA) as antigen-presenting
cells (APCs) in RPMI 1640 containing 100U/ml penicillin,
100µg/ml streptomycin, 2mM -glutamine (Cellgro, Manassas,
VA, USA), 7% FBS (Phenix Research Products, Candler, NC,
USA), 10mM HEPES (Fisher Scientific, Fair Lawn, NJ, USA),
and 50µM 2-ME (Sigma-Aldrich, St. Louis, MO, USA). Pep-
tides used for ex vivo restimulation NP peptide 216–230 (RIAY-
ERMCNILKGKF), NP peptide 146–159 (ATYQRTRALVRTGM),
matrix peptides 164–179 (SHRQMVTTTNPLIRH), and matrix
(M) peptide 211–226 (QARQMVQAMRTIGTH) were synthe-
sized by New England Peptide (New England Peptide Inc., Gard-
ner, MA, USA). Following restimulation for 2 h, Brefeldin A
(Sigma-Aldrich) was added to T cell cultures at 10µg/ml and
maintained throughout the final 2–4 h of incubation. In some
experiments, T cells were restimulated for 4–6 h, and Brefeldin A
was added over night. After a total of 4–18 h in culture, T cells
were surface stained with anti-CD4 and anti-CD8 antibodies as
described above and fixed in 4% paraformaldehyde. Cells were
then stained in saponin buffer (PBS containing 1% BSA, 0.1%
NaN3, and 0.25% saponin) containing antibodies to IFN-γ (eBio-
science Cat# 17-7311-82 RRID:AB_469504) and TNF-α (eBio-
science Cat# 12-7321-81 RRID:AB_466198) for 40min at room
temperature in the dark. Cells were then washed and resuspended
for FACS analysis. Cells were analyzed as described above.
ELISA for Detection of Anti-Influenza IgG2a
Antibodies
Ninety-six well plates were coated with x31/Ova virus (5 106
EID50/ml) diluted in PBS overnight. Plates were washed with PBS
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and blocked for 1 h with PBS containing 2% FBS and 10mM
HEPES. Serum was added to the plates in blocking buffer and
serially diluted twofold. After 2–3 h incubation at room tem-
perature, alkaline phosphatase-conjugated goat anti-mouse IgG2a
was added (Southern Biotech Associates, Birmingham, AL, USA)
for 1 h at room temperature. Plates were developed using p-
nitrophenyl phosphate (p-NPP) after a 15-min incubation in the
dark. Absorbancewas read at 405 nmand endpoint titerswere cal-
culated based on the dilution that gave two times the background
optical density using serum from a naïve mouse as described (12).
Statistics
Statistical significance between experimental groups was deter-
mined by one-way ANOVA followed by Tukey’s test using Prism
6.0 (Graph Pad Software).
Results
To demonstrate the in vivo protective efficacy of a single-
dose intranasal vaccine using CpG and inactivated x31/Ova
(CpG+ Inact) mice were immunized and then challenged with
a heterologous virus 4weeks later. Subsequently, viral titers were
measured 7 days post challenge. Viral burden in unimmunized
groups were significantly higher than in CpG+ Inact immunized
mice (Figure 1). As expected, mice immunized with live x31/Ova
had no appreciable levels of virus by day 7 (27). Sterilizing immu-
nity was not observed with either immunization, as priming with
H3N2 virus and challenging with H1N1 avoid contribution of
antibody-mediated protection to H and N. Thus, the results sug-
gest that a single immunization with CpG+ Inact provides partial
protection and may induce memory T cell responses capable
of reducing viral titers and morbidity associated with a lethal
heterosubtypic challenge.
To investigate the immunostimulatory capacity of this mucos-
ally administered CpG-based vaccine, inflammatory cytokines,
and chemokines were analyzed in the lung 1 day after intranasal
administration. For inactivated influenza and x31/Ova cohorts,
modest cytokine induction was observed characterized by IL-6
and tumor necrosis factor alpha (TNF-α) transcript upregulation.
In contrast, immunization with CpG+ Inact induced high levels
of nearly all inflammatory and chemotactic transcripts tested
(Figure 2A). TLR9 transcripts were also upregulated in the lung
indicating a positive-feedback loop of cells capable of inducing
inflammation. Next, the amount of viral PA copies present in
the lung was determined 1 day after immunization. As shown
in Figure 2B, only administration of live virus generated appre-
ciable levels of the PA gene, confirming the attenuation of the
vaccination strain.
Innate immune cells, including APC, play important roles in
initiation and maintenance of appropriate immune responses to
influenza infection (28–31). To determine whether innate immu-
nity was modulated after immunization, a number of APC popu-
lations were examined in lymphoid tissues and the lung.
In contrast to x31/Ova infection, CpG+ Inact immunization
resulted in increased frequencies of innate immune cells in the
DLN 1 day after immunization (Figure 3A). Rapid migration
of CD11c+/MHCII+ cells as well as CD11b+ macrophages was
observed in the DLNs (Figure 3B). Immunization also induced
FIGURE 1 | CpG immunization lowers viral titers after a heterosubtypic
influenza challenge. BALB/cByJ mice were immunized intranasally and
4weeks later challenged with 10LD50 of PR8. Seven days post challenge
mice were euthanized and viral titers were determined via qRT-PCR. The
amount of influenza RNA is shown as the PA copy number/100 ng of cDNA
and is relative to a standard curve generated using known amounts of the IAV
PA gene as described in the section “Materials and Methods.” Results are
representative of two independent experiments (n= 4–5 mice per group),
mean PA copy number+SEM. *p<0.05, ***p<0.001, ****p<0.0001.
FIGURE 2 | CpG immunization induces the transcription of cytokine
and inflammatory genes in the lung. (A) BALB/cByJ mice immunized with
the indicated regimens were euthanized 1 day after intranasal administration.
RNA was extracted from whole lungs and qRT-PCR performed. Amount of
mRNA transcripts for TLR9 and cytokines/chemokines is shown as arbitrary
units relative to the amount of GAPDH mRNA present in each sample.
Dashed line represents uninfected controls. (B) Influenza PA gene copy
number was assessed in whole lungs 1 day after immunization as in Figure 1.
Dashed line represents the limit of detection for the assay. Results represent
the mean+SD of three to four mice per group *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
significant increases in the lung-resident CD103+ migratory
DCs to the DLN; however, there were no detectable changes in
the frequency of CD8+ DCs after any treatment (Figure 3C).
To determine if vaccination induced APCs had the capacity to
prime adaptive immune responses, expression of the costimu-
latory molecule CD86 was measured in the DLN populations.
Upregulation of CD86 in CD11c+/MHCII+ and CD8+ DCs was
observed, indicating that these cells may initiate naïve T cell
responses (Figure 3D).
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FIGURE 3 | CpG immunization induces APC maturation in the DLN.
BALB/cByJ mice were immunized intranasally. (A) Representative FACS plots
from the DLN at day 1 post immunization. Innate immune populations were
enumerated at day 1 (B) and day 3 (E) by flow cytometry. CD8+ DCs and
CD103+ DCs were enumerated at day 1 (C) and day 3 (F). Gated innate
immune populations were assessed for their surface expression of the
costimulatory molecule CD86 (D,G). CD69 upregulation on the surface of
CD4 and CD8 T cells in the draining lymph nodes 3 days after immunization
(H). Graphs represent two separate experiments (n= 3–5 mice per group)
with data given in mean percentageSD. *p<0.05 **p<0.01, ***p<0.001.
The results here are consistent with other published studies
suggesting that the intranasal administration of CpG induces APC
maturation in the DLNs (32). In contrast to the diverse influx of
cells seen in the DLN at day 1, only the frequency of CD11b+ cells
was increased after CpG immunization (Figures 3E,F). By day 3,
minimal changes were observed in CD86 expression (Figure 3G).
To determine the functional consequences of APC maturation,
CD69 (a surface marker typically upregulated after T cell activa-
tion) expression on T cells was measured at day 3 in the lymph
node (33, 34). Here, PR8 infection was used as a positive control.
In the DLNs, CD69 expression was differentially upregulated in
CD8 cells after CpG+ Inact or influenza immunizationwhile only
PR8 infection resulted in increases in CD4 cells (Figure 3H).
Interestingly, the mature APC phenotype observed in the CD8+
DC subset did correspond with the activation status of the CD8
cells (Figure 3H). These results suggest that CpG+ Inact immu-
nization induces a population of activated cells derived from naïve
precursor cells in the DLN.
In contrast to the DLN, APC influx and activation were sus-
tained in the lung until at least day 3. In the lung, we have
identified three populations of cells: (i) interstitial macrophages
(ii) alveolar macrophages, and (iii) conventional CD11c+ cells
each with unique responses to CpG immunization (Figure 4A).
While increases in the frequency of CD11c+ cells were not
observed until day 3, interstitial macrophage influx was signif-
icantly higher at both time points in CpG+ Inact immunized
groups (Figures 4B,F). CpG+ Inact treatment reduced the per-
centage of alveolar macrophages (F4/80+/CD11c+) in the lung
similar to what has been reported for PR8 infection (35). Further-
more, we observed clear increases in the percentage of CD86+
cells (data not shown) as well as CD86 median fluorescence
intensity (MFI) in CD11c+ and interstitial macrophages at day 1
and day 3 (Figures 4C,G). Interestingly, infection with x31/Ova
demonstrated relatively low CD86 MFI levels, a similar profile
to that of inactivated virus. CD103+ migratory dendritic cell
populations were also examined in the lung. At day 1, increases
in CD103+ DCs were observed (Figure 4D); however, these cells
were decreased in frequency by day 3 (Figure 4H). Next, we
wanted to determine the frequency of cells expressing the recep-
tor for CpG (TLR9) in the lung. Significant increases in TLR9-
expressing CD11c+ dendritic cells were observed over the time
course compared to both inactivated and live virus immunizations
(Figures 4E,I). Lastly, CD69 expression on T cells was exam-
ined in the lung 3 days after immunization. Compared with PBS
and inactivated virus, both CpG+ Inact and PR8 immunization
induced significant increases in CD69+ T cells. We conclude
that immunization with CpG and inactivated virus leads to a
phenotypic maturation of APCs where favorable conditions exist
for and early T cell activation in the DLN (Figure 3) and lung
(Figure 4).
Cytotoxic T cells have been shown to be important effectors
in IAV infections in heterosubtypic protection in both humans
(19) and mice (16). Thus, we sought to determine if T cells
with cytolytic potential could be generated after vaccination. Six
days after immunization, mice were euthanized and Granzyme B
(GrB) expression in T cells was measured. As a positive control
for GrB expression, infection with a sublethal dose of PR8 was
used and induced >97% GrB+ CD4 and CD8 cells as expected
(26, 36). Interestingly, compared to the x31/Ova infection,
CpG+ Inact immunized mice had a much higher percentage of
GrB positive cells (Figure 5A). While the percentage of CD4 and
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FIGURE 4 | CpG immunization induces APC maturation in the lung.
BALB/cByJ mice were immunized intranasally. (A) Representative FACS plots
from the lung at day 1 show (i) interstitial macrophages (F4/80+), (ii) alveolar
macrophages (F4/80+ CD11c+), and (iii) conventional DCs (CD11c+). DCs,
interstitial macrophages, and alveolar macrophage populations were
enumerated at day 1 (B) and day 3 (F) in the lungs. Innate immune cell
populations were assessed for their surface expression of the costimulatory
molecule CD86 by measuring the median fluorescence intensity (MFI) (C,G).
The influx of CD103+ dendritic cells (D,H) and TLR9+ (E,I) cells was also
enumerated after immunization. CD69 upregulation on CD4 and CD8 T cells
in the lungs 3 days after immunization (J). Graphs represent two separate
experiments (n=3–5 mice per group) with data given in mean
percentageSD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
CD8 T cells expressing GrB in inactivated or x31/Ova cohorts was
<5%, immunizationwithCpG+ Inact resulted in 40%GrB+ CD4
cells and 20%GrB+ CD8 cells (Figure 5B). Similarly, theGrBMFI
was highest in CpG- and PR8-immunized mice. As expected, the
CD8 MFI was universally higher than the CD4 GrB MFI. These
results suggest that while inactivated influenza weakly induces T
cell responses in the lung, addition of CpG enhances the effector
profile and induces T cells with cytotoxic capabilities.
To further characterize the effector T cell response after immu-
nization, cytokine production in the lung was assessed by intra-
cellular staining. Previously, we have shown that restimulation
with a peptide cocktail consisting of NP epitopes induces strong
T cell cytokine production during the influenza response (26)
and allows us to assess cross-reactive T cells after vaccination.
At day 6, most cytokine-producing T cells were TNF-α+ while
low frequencies of IFN-γ+ cells were observed after peptide
restimulation (Figure 5C). A small cohort of these cells was
dual IFN-γ and TNF-α producing cells in CpG+ Inact and
x31/Ova-primed groups (Figure 5D). Collectively, these results
demonstrate that effector CD4 and CD8 cells were recruited
to the lung during immunization and acute infection, and that
antigen-specific responses were generated by day 6. Further-
more, these data suggest that different priming events occur
between a natural infection and CpG+ Inact immunization,
which lead to differences in quality and quantity of effector
T cells.
Next, we sought to determine if the effector cells identified in
the lung persisted into memory. Expression of CD44 has been
shown as a memory T cell marker and is present on the surface
of resting memory cells (37). Thus, 28 days after immunization,
CD44+ cells were enumerated in the lungs and spleens. Although
no differences in CD44 expression were observed in splenocytes
(data not shown), CpG+ Inact induced significant increases in
the number of CD8+/CD44+ T cells in the lungs (Figure 6A).
Next, ex vivo cytokine analysis was performed on cells isolated
from the lungs and spleens. Unexpectedly, only increases in
antigen-specific responses were detected in x31/Ova-immunized
groups (Figures 6B,C). Therefore, CpG+ Inact immunization
induced CD44+ cells in the lungs; however, in the absence of
a secondary challenge, cytokine responses were only detected
in x31/Ova-infected animals. To confirm that the protection
generated by our vaccine was in the absence of pre-existing
antibodies, serum was collected 5weeks after immunization and
anti-x31/Ova IgG2a titers were measured. Antibody responses to
the virus were only generated by prior infection (Figure 6D).
Indeed, endpoint titers were very low after CpG+ Inact immu-
nization, and only one out of four mice generated any anti-
influenza antibody response (Figure 6E). Thus, the protection
mediated by CpG+ Inact immunization does not depend on
IgG2a antibodies.
Based on the requirement for secondary effector T cell
responses to mediate protection in highly pathogenic infections
(38), it was important to determine the frequency of GrB+
and antigen-specific cytokine-producing cells after influenza
challenge. Mice were immunized and 4–5weeks later challenged
with a lethal dose of PR8. Five days after challenge, lungs
were harvested and cells were analyzed for GrB expression.
In contrast to mock or inactivated immunizations, adminis-
tration of CpG+ Inact or x31/Ova significantly enhanced the
number of GrB+ T cells within the lung (Figure 7A). To
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FIGURE 5 | CpG immunization and IAV infection induce effector T cell
responses in the lung. BALB/cByJ mice were immunized intranasally, mice
were euthanized, and lungs harvested at day 6. (A) Representative overlay
histograms show GrB expression after gating on CD4+, CD8+ T cells, or NK
cells in the lung. (B) Shown are the percentages of CD4, CD8, or NK cells
expressing GrB as well as the GrB MFI of each population. (C) Representative
FACS plots in the lung after ex vivo restimulation for 4–6 h with NP and M
peptides. (D) Absolute number of cytokine-producing CD4 and CD8 cells were
enumerated after restimulation. Single * in the CD4 quantification denotes
significance over all other groups as analyzed by ANOVA. Data represent two
independent experiments (n= 4–5 mice per group) given in mean percentage of
cytokine positive cells+SD *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
further quantify memory T cell responses after IAV challenge,
we sought to determine the number of cytokine expressing cells
at the site of infection. In mock- and inactivated-immunized
mice, the frequency of cytokine positive cells was low in both
CD4 and CD8 cells at day 5 post challenge indicative of the
lack of a primed T cell response (Figure 7B). In CpG+ Inact
immunized mice, T cell responses were apparent, characterized
by IFN-γ and TNF-α-positive cells (Figure 7B). Furthermore,
a robust memory response was initiated with high frequencies
of dual cytokine positive T cells after x31/Ova immunization
and PR8 challenge (Figure 7B). CpG+ Inact immunization pro-
duced increased trends of cytokine responses compared to PBS
groups; however, significance was not achieved (Figure 7C).
These results suggest the presence of a naïve T cell response
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FIGURE 6 | Low-dose influenza infection generates antigen-specific
memory cells in the spleen and lung. BALB/cByJ mice were vaccinated with
the indicated regiments and euthanized 4weeks later. (A) Absolute numbers of
CD44+ T cells were quantified in the lungs. Intracellular cytokine staining on
cells isolated from the (B) lung or (C) spleen was performed after an 18-h
incubation with NP and M peptides. Shown is the number of IFN-γ positive
cells. Data represent two independent experiments (n=4–5 mice per group)
with data given in mean percentage of CD44+ or cytokine positive cells+SD.
*p<0.05, ****p<0.0001. (D) Five weeks post immunization, serum was
collected and serially diluted and the optical density at 405 nm was determined.
(E) Endpoint titers for the anti-x31/ova IgG2a from samples in (D). Data are
given in meanSD. *p<0.05, ****p<0.0001.
after challenge in mock or inactivated groups, highlighted by
the lack of robust T cell responses at day 5. In contrast,
the recall of memory T cells in CpG+ Inact immunized or
x31/Ova-infected animals was seen by the increased frequen-
cies of GrB and cytokine positive T cells early after influenza
challenge.
Discussion
The use of pattern recognition receptor (PRR) agonists is becom-
ing increasingly widespread as potential vaccine adjuvants for
a number of diseases including IAV. Here, we describe a novel
influenza vaccine platform based on the generation of antigen-
specific CD4 and CD8 T cells capable of reducing viral titers
after lethal IAV challenge. Single dose, intranasal administra-
tion of CpG+ Inact resulted in the production of proinflam-
matory cytokines, mobilization of APC populations, and the
establishment of effector T cell responses by day 6 post admin-
istration. Our results suggest that effector T cells transitioned
into memory cells capable of rapidly responding in the lung
upon reinfection to reduce viral replication in an antigen-specific
manner.
The vaccine platform described here has numerous advan-
tages compared to other IAV vaccines. First, the use of the
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FIGURE 7 | CpG immunization induces functional memory responses
at day 5 post challenge with a heterosubtypic IAV infection.
BALB/cByJ mice were vaccinated as indicated. Four to five weeks post
immunization, mice were challenged with a 10 LD50 of PR8. (A) Lungs were
harvested 5days after infection, and the absolute number of GrB+ T and NK
cells were enumerated via flow cytometry. (B) Representative FACS plots in
the lung after ex vivo restimulation for 4–6 h with NP and M peptides.
(C) Percentage of cytokine-producing CD4 and CD8 cells were enumerated
after restimulation. Data represent two independent experiments (n= 4–5
mice per group) given in mean percentage of cytokine positive cells or
absolute number of GrB+ cells+SD. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
PRR agonist, CpG, as an innate immune modulator has been
approved for use in humans, but is not yet incorporated into
current IAV vaccine preparations. In contrast to vaccines admin-
istered via the intradermal, subcutaneous, or intramuscular route,
intranasal immunization induces immunity at mucosal surfaces
where an effective local immune response is required following
IAV infection. Additionally, this vaccine induces memory T cell
responses in the lung capable of responding to internal con-
served viral epitopes, which are thought to greatly aid in protec-
tion against heterosubtypic IAV challenges. Lastly, a single dose
administered without boosting is a clear advantage for vaccine
compliance in human populations.
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Pattern recognition receptor agonists, especially CpG, can pro-
tect against infectious agents in two ways. One is non-specific
immune activation involving themodulation ofmacrophages, NK
cells, inflammatory cytokines, and polyreactive IgM molecules.
Numerous studies have demonstrated the protective activation
of innate immunity by exposing mice to a single dose of CpG
against a number of pathogens including Ebola, anthrax, and
malaria (39), which can induce non-specific protection lasting
between 1 and 3weeks. Additionally, we have observed protection
against weight loss after IAV infection in an antigen-independent
manner using CpG (Brown and Swain, unpublished). Many stud-
ies that examine the efficacy of CpG-based vaccines report sur-
vival, weight loss, and viral replication of IAV 1–3weeks after
the final boost or immunization (40–44). Even though in the
majority of these studies antigen-specific T cell responses are
quantified, the experiments performed under these conditions do
not allow sufficient time after immunization for the non-specific
effects of CpG immunization to wane. In contrast, our study
allows the development of T cell memory responses (Figures 5
and 6) that participate in partial inhibition of viral replication
(Figure 1).
Following an infection with a homotypic virus, strain-specific
humoral immunity is induced and prevents reinfection upon sub-
sequent challenges. To date, IAV vaccines use this approach to
generate strain-specific antibodies against outer coat proteins in
the common seasonal influenza strains. In a heterotypic influenza
challenge model, T cells reactive to conserved viral proteins, such
as NP and M, are capable of providing protection and persist in
the tissues and secondary lymphoid organs as a source of mem-
ory cells to respond to serologically distinct IAV infections (19).
However, it is unlikely that cross-reactive CTLs provide sterilizing
immunity, as some degree of antigen processing and presentation
must occur to initiate a memory response (45). Here, effector
functions provided by CTLs (Figure 7) may have substantial
impacts on viral replication (Figure 1) and therefore morbidity
andmortality. Similar to infection with x31/Ova, vaccination with
CpG+ Inact does not provide sterilizing immunity after hetero-
subtypic challenge but reduces viral burden. Previous work from
our lab suggests that reducing viral replication is one of the deter-
minants for a positive survival outcome (26). Therefore, the pro-
tection provided byCD4 andCD8T cells generated by vaccination
is significant to the outcome of a heterotypic challenge.
Other factors likely contributed to the lack of total viral clear-
ance by day 7. Upon challenge, a considerable population of dual
cytokine-positive T cells was present in x31/Ova-immunizedmice
but not CpG+ Inact-immunized mice. This suggests differences
in priming between the two cohorts results in differences in qual-
ity of protection. Surprisingly, little innate immune modulation
was observed in x31/Ova mice compared to CpG+ Inact mice
(Figures 2–4), suggesting that while inducing inflammation and
APC modulation is important in a vaccine setting, low levels of
viral replication may be the best strategy to induce robust T cell
memory responses (46). Alternatively, T cell responses generated
by CpG vaccination could be below a certain threshold, and thus
vaccinationwould fail to fully protect from infection (47).Wehave
attempted to enumerate the resting population of memory T cells
in CpG+ Inact-immunized mice 28 days after infection. While
differences in CD44 expression were observed CD8 cells in the
lung (Figure 6A), ex vivo restimulation and intracellular cytokine
analysis revealed little difference between mock and CpG+ Inact
immunized groups. However, a trend of increased cytokine-
positive cells combined with increases in CD44 expression in the
lung suggests that CpG+ Inact vaccination could be inducing
resident memory T cells poised for effector function (48).
Conversely, the inability to detect the significant levels
of cytokine-producing cells by peptide restimulation in
CpG+ Inact-immunized mice could be due to the low frequency
of memory cells. The experiments here specifically look at
responses to two peptides derived fromM and NP each. Thus, the
peptide restimulation might not be activating the full memory
T cell repertoire, as memory responses could be generated to
multiple conserved T cell epitopes (M, NP, PB1, PA) as well as
non-conserved epitopes (H and N) present in the inactivated
whole virus preparations. Furthermore, as the memory T cell
population induced by vaccination may make up <0.5–2% of the
total cells in the lung, isolating and staining these cells may be
inefficient and not reflective of the true population. Nonetheless,
the data suggest that memory responses are generated in
CpG+ Inact vaccinated mice as antigen-specific T cells are
detected in the lungs 5 days post challenge (Figure 7).
Unexpectedly, the preparation of antigen played an important
role in assessing the contribution of memory T cells to heterosub-
typic protection. IAV can be inactivated in many different ways,
each inducing unique immune responses. While heat-inactivated
virus is less antigenic than othermethods of viral inactivation (49),
effector and memory T cell responses can clearly be generated
when it is combined with CpG (Figures 5 and 7). Interestingly,
very little influenza-specific class-switched IgG2a antibody was
detected in the serum of immunized mice 4weeks after immu-
nization (Figures 6D,E), further supporting the pronounced role
of memory T cells in heterosubtypic protection. One study found
immunizing with a single dose of CpG and formalin-inactivated
IAV increased anti-IAV antibodies 4weeks post immunization in
the serum and saliva (50). However, themodulation of the cellular
immune response, measured by proliferation assays and CTL
responses, was not observed. The difference between our study
and the Moldoveanu report are likely due to antigen processing
and presentation of the viral peptides.
Nonetheless, partial immune protection can serve as a frame-
work to enhance and modify the existing platform to gener-
ate a vaccine with satisfactory efficacy and safety. For example,
nanoparticle conjugation could be used for a dose sparing effect
and enhanced protection. Other ways of modulating immunity
could be through using multiple PRR ligands to generate a syn-
ergistic T cell response when combined with CpG. Our findings
demonstrate a single dose of CpG, administered intranasally,
can control viral replication and represents a possible strategy
for developing vaccines against heterosubtypic infections in the
future.
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